Pharmacists in Oconto, WI Accepting Medicare
3 Pharmacists found. Showing 1 - 3
 Mr. Thomas Lotter Sr., RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 126 Charles St, Oconto, WI 54153 Phone: 920-834-5251 Fax: 920-834-9801 |
Mr. David Miskulin, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1008 Main St, Oconto, WI 54153 Phone: 920-834-4455 Fax: 920-834-3655 |
 Joyce Hie Hie Yii, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1008 Main St, Oconto, WI 54153 Phone: 920-834-4455 |
News Archive
Patient-Centered Primary Care Collaborative National Summit to focus on reforming health care delivery
The nation's top thought leadership and advocates for the patient centered medical home (PCMH) will convene a national meeting in Washington, DC Oct. 22 to unite around the Summit's goal to build, expand and support a fundamentally improved model for health care delivery.
New health reform law to benefit 30 million women: Commonwealth Fund report
Thirty million women will benefit from the new health reform law over the next decade, either through new or strengthened insurance coverage, according to a new report from The Commonwealth Fund. In the first analysis of its kind, the authors report that the law will stabilize and reverse the growing exposure to health costs that women now experience by subsidizing health insurance for up to 15 million currently uninsured women, and strengthening existing coverage for 14.5 million women who are considered underinsured-those who have health coverage that does not adequately protect them from high medical expenses.
New campaign to educate about peripheral arterial disease
More than 8 million men and women - one in 20 adults - have peripheral arterial disease (P.A.D), a largely unrecognized condition which puts them at risk for heart attack and stroke.
Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
Alzheimer's Drug Discovery Foundation announces first round of awards of Diagnostics Accelerator initiative
The Alzheimer's Drug Discovery Foundation announced today the first group of researchers who will receive funding through its Diagnostics Accelerator, a new research program that aims to fast-track the development of diagnostic tools and biomarkers for Alzheimer's disease and related dementias.
› Verified 4 days ago
Counselors
Dentists
Pharmacists
Occupational Therapists
Clinical Social Workers